Marianne Samir Makboul Issac

Dr. Marianne Samir Makboul Issac

Institute for Research in Immunology and Cancer, University of Montreal
+1
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2021 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
SMSheri A. C. McDowell
Sheri A. C. McDowell
RLRobin B. E. Luo
Robin B. E. Luo
AAAzadeh Arabzadeh
Azadeh Arabzadeh
SDSamuel Doré
Samuel Doré
NBNicolas C. Bennett
Nicolas C. Bennett
DQDaniela F. Quail
Daniela F. Quail

1 October 2019 in Neoplasia
Verified
Journal Article
Open access
Marianne Samir Makboul IssacMarianne Samir Makboul Issac
Marianne Samir Makboul Issac
EYEinas Yousef
Einas Yousef
MTMuhammad Ramzan Tahir
Muhammad Ramzan Tahir
LGLouis Gaboury
Louis Gaboury
Breast cancer is a heterogeneous disease comprising the estrogen receptor (ER)-positive luminal subtype which is subdivided into luminal A and luminal B and ER-negative breast cancer which includes the triple-negative subtype. This study has four aims: 1) to examine whether Minichromosome Maintenance (MCM)2, MCM4, and MCM6 can be used as markers to differentiate between luminal A and luminal B subtypes; 2) to study whether MCM2, MCM4, and MCM6 are highly expressed in triple-negative breast cancer, as there is an urgent need to search for surrogate markers in this aggressive subtype, for drug development purposes; 3) to compare the prognostic values of these markers in predicting relapse-free survival; and 4) to compare the three approaches used for scoring the protein expression of these markers by immunohistochemistry (IHC). MCM2, MCM4, MCM6, and MKI67 mRNA expression was first studied using in silico analysis of available breast cancer datasets. We next used IHC to evaluate their protein expression on tissue microarrays using three scoring methods. MCM2, MCM4, and MCM6 can help in distinction between luminal A and luminal B whose therapeutic management and clinical outcomes are different. MCM2, MCM4, MCM6, and Ki-67 are highly expressed in breast cancer of high histological grades that comprise clinically aggressive tumors such as luminal B, HER2-positive, and triple-negative subtypes. Low transcript expression of these markers is associated with increased probability of relapse-free survival. A positive relationship exists among the three scoring methods of each of the four markers. An independent validation cohort is needed to confirm their clinical utility.

11 May 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SMSheri A.C. McDowell
Sheri A.C. McDowell
SMSimon Milette
Simon Milette
SDSamuel Doré
Samuel Doré
MYMiranda W. Yu
Miranda W. Yu
MSMark Sorin
Mark Sorin
DQDaniela F. Quail
Daniela F. Quail
Obesity is characterized by chronic systemic inflammation and enhances cancer metastasis and mortality. Obesity promotes breast cancer metastasis to lung in a neutrophil-dependent manner; however, the upstream regulatory mechanisms of this process remain unknown. Here, we show that obesity-induced monocytes underlie neutrophil activation and breast cancer lung metastasis. Using mass cytometry, obesity favors the expansion of myeloid lineages while restricting lymphoid cells within the peripheral blood. RNA sequencing and flow cytometry revealed that obesity-associated monocytes resemble professional antigen-presenting cells due to a shift in their development and exhibit enhanced MHCII expression and CXCL2 production. Monocyte induction of the CXCL2–CXCR2 axis underlies neutrophil activation and release of neutrophil extracellular traps to promote metastasis, and enhancement of this signaling axis is observed in lung metastases from obese cancer patients. Our findings provide mechanistic insight into the relationship between obesity and cancer by broadening our understanding of the interactive role that myeloid cells play in this process.

1 July 2018 in Health Psychology Open
Verified
Journal Article
Open access
KWKatherine White
Katherine White
Marianne Samir Makboul IssacMarianne Samir Makboul Issac
Marianne Samir Makboul Issac
CKClaire Kamoun
Claire Kamoun
JLJessica Leygues
Jessica Leygues
SCSimon Cohn
Simon Cohn
This article explores the ways in which people cope with social and clinical dimensions of their chronic conditions. Existing literature was reviewed to categorize factors identified as being key. They were sorted into six groupings which are reflected by the acronym THRIVE: therapeutic interventions, habit and routine, relational-social, individual differences, values and beliefs, and emotional factors. We found little evidence to suggest different conditions prompt unique coping responses; rather, a range of common factors were observed across diverse conditions. The THRIVE framework not only summarizes current literature but provides a starting point for further research and development of future interventions.

16 May 2013 in Molecular Diagnosis & Therapy
Verified
Journal Article
Closed access
PDF file
MSMona F. Shabana
Mona F. Shabana
AMAmal A. Mishriki
Amal A. Mishriki
Marianne Samir Makboul IssacMarianne Samir Makboul Issac
Marianne Samir Makboul Issac
SBSameh W. G. Bakhoum
Sameh W. G. Bakhoum